CRISPR Therapeutics AG (CRSP) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, CRISPR Therapeutics reported revenue of $3.5M, down 90.6% from $37.3M the year before. Net income was -$581.6M (a -16569.8% net margin), or -$6.47 per diluted share. Operating margin was -18933.6%. Operating activities generated -$345.0M of cash, leaving -$345.9M of free cash flow. At fiscal year end, CRISPR Therapeutics held $2.27B in total assets against $343.4M in total liabilities, including $347.6M of cash and equivalents.
Open the full interactive CRISPR Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
CRISPR Therapeutics Key Stats
| Share Price | $50.10 |
|---|---|
| Market Cap | $4.84B |
| Revenue YoY Growth | -90.6% |
| 52-Week Range | $44.34 – $73.97 |
| Shares Outstanding | 96.5 million (basic, 2026 Q2) |
CRISPR Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $719,000 | $915.0M | $1.2M | $371.2M | $37.3M | $3.5M |
| Operating Income | -$354.4M | $373.5M | -$673.2M | -$222.5M | -$466.6M | -$664.6M |
| Pre-Tax Income | -$348.1M | $379.5M | -$650.5M | -$150.7M | -$362.7M | -$578.0M |
| Income Tax | $809,000 | $1.9M | -$325,000 | $2.9M | $3.6M | $3.6M |
| Net Income | -$348.9M | $377.7M | -$650.2M | -$153.6M | -$366.3M | -$581.6M |
| Diluted EPS | -$5.29 | $4.70 | -$8.36 | -$1.94 | -$4.34 | -$6.47 |
CRISPR Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $889,000 | $864,000 | $1.5M | $10.2M |
| Net Income | -$106.4M | -$130.6M | -$122.9M | -$91.2M |
| Diluted EPS | -$1.17 | -$1.45 | -$1.28 | -$0.94 |
CRISPR Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.17B | $923.0M | $211.9M | $389.5M | $298.3M | $347.6M |
| Current Assets | $1.72B | $2.42B | $1.85B | $1.91B | $1.94B | $1.99B |
| Total Assets | $1.83B | $2.75B | $2.24B | $2.23B | $2.24B | $2.27B |
| Current Liabilities | $94.3M | $119.9M | $121.1M | $108.8M | $87.8M | $149.1M |
| Total Liabilities | $163.7M | $352.4M | $367.6M | $346.8M | $310.0M | $343.4M |
| Shareholders' Equity | $1.66B | $2.40B | $1.88B | $1.88B | $1.93B | $1.92B |
CRISPR Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$238.4M | $539.0M | -$495.7M | -$260.4M | -$142.8M | -$345.0M |
| Cash From Investing | -$541.2M | -$1.04B | -$258.7M | $374.6M | -$280.5M | -$31.8M |
| Cash From Financing | $1.02B | $250.9M | $38.6M | $62.7M | $332.0M | $426.0M |
| Free Cash Flow | -$256.7M | $457.3M | -$532.9M | -$269.8M | -$144.7M | -$345.9M |
Figures from CRISPR Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full CRISPR Therapeutics financials page for every line item.
CRISPR Therapeutics Company Profile
| Ticker | CRSP |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Zug |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001674416 |
Frequently Asked Questions
What was CRISPR Therapeutics' revenue in fiscal 2025?
CRISPR Therapeutics (CRSP) reported revenue of $3.5M for fiscal 2025.
What is CRISPR Therapeutics' annual revenue history?
CRISPR Therapeutics' annual revenue by fiscal year: 2020: $719,000; 2021: $915.0M; 2022: $1.2M; 2023: $371.2M; 2024: $37.3M; 2025: $3.5M.
What was CRISPR Therapeutics' net income in fiscal 2025?
CRISPR Therapeutics reported net income of -$581.6M for fiscal 2025.
What was CRISPR Therapeutics' earnings per share (EPS) in fiscal 2025?
CRISPR Therapeutics' diluted EPS was -$6.47 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did CRISPR Therapeutics generate in fiscal 2025?
CRISPR Therapeutics generated -$345.9M of free cash flow in fiscal 2025.
What was CRISPR Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), CRISPR Therapeutics reported revenue of $10.2M.
How many shares of CRISPR Therapeutics are outstanding?
CRISPR Therapeutics reported a weighted average of 96.5 million basic shares outstanding in 2026 Q2.
What is CRISPR Therapeutics' market cap?
Based on its latest closing price, CRISPR Therapeutics (CRSP) has a market capitalization of about $4.84B.
When does CRISPR Therapeutics' fiscal year end?
CRISPR Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is CRISPR Therapeutics headquartered?
CRISPR Therapeutics lists its business address in Zug in its SEC filings.
CRISPR Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →